Recombinant adenovirus encoding FAT10 small interfering RNA inhibits HCC growth in vitro and in vivo

被引:14
作者
Chen, Jingxiang [1 ]
Yang, Li [2 ]
Chen, Hongxu [1 ]
Yuan, Tao [1 ]
Liu, Menggang [1 ]
Chen, Ping [1 ]
机构
[1] Third Mil Med Univ, Daping Hosp, Dept Hepatobiliary Surg, Chongqing 400042, Peoples R China
[2] Third Mil Med Univ, Daping Hosp, Dept Cardiol, Chongqing 400042, Peoples R China
关键词
HCC; PAT10; RNA interference; Carcinogenesis; Strategy; HEPATOCELLULAR-CARCINOMA; GENE-THERAPY; APOPTOSIS; RESECTION; CANCERS; PROTEIN; METASTASIS; EXPRESSION; AGENTS; CELLS;
D O I
10.1016/j.yexmp.2014.01.001
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Hepatocellular carcinoma is an aggressive and rapidly fatal malignancy representing the common cancer worldwide. The specific cellular gene involved in carcinogenesis has not been fully characterized. The ubiquitin-like modifier FAT10, recently reported to be overexpressed in 90% of hepatocellular carcinoma carcinomas, was attributed to transcriptional upregulation upon the loss of p53 and induced chromosome instability in long-term in vitro culture. However, the exact function of FAT10 in hepatocellular carcinoma is not clear. In the present study, we utilized adenovirus-mediated RNA interference to knock down FAT10 expression in hepatocellular carcinoma cells and observed its effects on hepatocellular carcinoma cell growth in vitro and in vivo. The results demonstrated that interference of FAT10 could inhibit cell proliferation by inhibiting the cell cycle S-phase entry and inducing cell apoptosis. In addition, in vivo experiments showed that adenovirus Ad-siRNA/FAT10 significantly suppressed tumor growth and prolonged the lifespan of tumor-bearing mice. These results suggest that knockdown of FAT10 by adenovirus-delivered siRNA may be a promising therapeutical strategy for treatment of hepatocellular carcinoma. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:207 / 211
页数:5
相关论文
共 32 条
[1]   Identification and analysis of a novel member of the ubiquitin family expressed in dendritic cells and mature B cells [J].
Bates, EFM ;
Ravel, O ;
Dieu, MC ;
Ho, S ;
Guret, C ;
Bridon, JM ;
AitYahia, S ;
Briere, F ;
Caux, C ;
Banchereau, J ;
Lebecque, S .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (10) :2471-2477
[2]   Structure determination of the small ubiquitin-related modifier SUMO-1 [J].
Bayer, P ;
Arndt, A ;
Metzger, S ;
Mahajan, R ;
Melchior, F ;
Jaenicke, R ;
Becker, J .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 280 (02) :275-286
[3]   Multimodal approaches to the treatment of hepatocellular carcinoma [J].
Cabibbo, Giuseppe ;
Latteri, Federica ;
Antonucci, Michela ;
Craxi, Antonio .
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2009, 6 (03) :159-169
[4]   Hepatocellular carcinoma: Current management and future trends [J].
Carr, BI .
GASTROENTEROLOGY, 2004, 127 (05) :S218-S224
[5]   Valosin-containing protein is a multiubiquitin chain targeting factor required in ubiquitin-proteasome degradation [J].
Dai, RM ;
Li, CCH .
NATURE CELL BIOLOGY, 2001, 3 (08) :740-744
[6]   Hepatocellular carcinoma - An epidemiologic view [J].
El-Serag, HB .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2002, 35 (05) :S72-S78
[7]  
Fatourou EM, 2009, EXPERT REV ANTICANC, V9, P1499, DOI [10.1586/era.09.103, 10.1586/ERA.09.103]
[8]   New Surgical Approaches in the Treatment of Hepatocellular Carcinoma [J].
Hoffmann, K. ;
Schmidt, J. .
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2009, 47 (01) :61-67
[9]   Dual therapeutic effects of interferon-α gene therapy in a rat hepatocellular carcinoma model with liver cirrhosis [J].
Huang, Kai-Wen ;
Huang, Yung-Chi ;
Tai, Kuo-Feng ;
Chen, Bo-Hua ;
Lee, Po-Huang ;
Hwang, Lih-Hwa .
MOLECULAR THERAPY, 2008, 16 (10) :1681-1687
[10]   FAT10 level in human gastric cancer and its relation with mutant p53 level, lymph node metastasis and TNM staging [J].
Ji, Feng ;
Jin, Xi ;
Jiao, Chun-Hua ;
Xu, Qin-Wei ;
Wang, Zi-Wei ;
Chen, Yue-Liang .
WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (18) :2228-2233